---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-018318"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2026-05-26T12:03:22+00:00"
generated_at: "2026-05-26T12:05:25.342304+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Genprex reports positive predictive biomarker data for Reqorsa in NSCLC at ASCO 2026

## Summary
- In NSCLC patients, Trop-2 H-score >100 and PTEN H-score <100 correlated with prolonged PFS (p=0.05, p=0.03).
- Data from 18 patients across Acclaim-1 (osimertinib), Acclaim-2 (pembrolizumab), and Acclaim-3 (atezolizumab) trials.
- High (3+) Trop-2 expression showed near-significant correlation with PFS (p=0.053); will be further investigated as biomarker.
- In SCLC patients, Trop-2 levels were universally low; no significant correlation with PFS observed.

## SEC filing metadata
- accession: 0001437749-26-018318
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2026-05-26T12:03:22+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774926018318/0001437749-26-018318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774926018318/gnpx20260515_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-018318
- JSON: https://secwatch.observer/filing/0001437749-26-018318.json
- Plain text: https://secwatch.observer/filing/0001437749-26-018318.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.